(Reuters) -German science and technology group Merck is open to more acquisitions for its Life Science business after ...

Merck KGaA’sMRK-1.94%decrease ... sales grow faster than previously expected over the medium term. The life-sciences and chemicals group lifted its mid-term outlook for its electronics business ...

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward ...

Merck MRK-1.63%decrease; red down pointing triangle KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

A drug against fungal infections in cancer patients can last twice as long in people with obesity, and may make chemotherapy ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent pipeline setbacks but raised its electronics forecast, citing strong ...

GERMAN science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for US$600 million, it said ahead of its Capital ...